Tech Company Financing Transactions
IMIDomics Funding Round
DNS Capital, Bristol-Myers Squibb and Pritzker Group Venture Capital participated in a $16.5 million Series A funding round for IMIDomics. The round was announced on 7/29/2021.
Transaction Overview
Company Name
Announced On
7/29/2021
Transaction Type
Venture Equity
Amount
$16,500,000
Round
Series A
Investors
DNS Capital (Lead Investor) (Michael Pucker)
Proceeds Purpose
With this new funding, we will be able to build on this foundation to fuel our precision discovery efforts and accelerate technologies that are critical to the further development of new IMID treatments, while expanding our teams in the US and Europe.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
San Francisco, CA 94105
USA
San Francisco, CA 94105
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
IMIDomics, Inc. is a biotechnology company focused on the discovery and development of new medicines for the treatment of immune-mediated inflammatory diseases (IMIDs).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Juan Harrison
Chief Financial Officer
Susan Vuong
Chief Medical Officer
Sara Marsal
Chief Operating Officer
Manuel López-Figueroa
Chief Scientific Officer
Toni Julià
Browse more venture capital transactions:
Prev: 7/29/2021: BioIntelliSense venture capital transaction
Next: 7/29/2021: AdaptX venture capital transaction
Share this article
About Database of VC Transactions
We report on all VC transactions involving tech companies. All VC database entries on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs